AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7043751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine 20 mg/kg and pyrimethamine 1.0 mg/kg (Group 1)
Number of subjects: 68
Study 7043751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine 30 mg/kg and pyrimethamine 1.5 mg/kg (Group 2)
Number of subjects: 68
Study 7043751 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 10 mg/kg 8 hourly for 5 days plus sulfadoxine 20 mg/kg and pyrimethamine 1.0 mg/kg (Group 3)
Number of subjects: 68
Study 29339470 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher covering the naturalization application fee
Number of subjects: 0
Study 29339470 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nudges for low-income immigrants
Number of subjects: 0
Study 27327217 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0
Study 27327217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24360749 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-enriched diet (43g/d)
Number of subjects: 40
Study 24360749 — intervention group
Group type: COMPARATOR
Intervention: Western-type (control) diet
Number of subjects: 40
Study 24321091 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 DNA vaccine at months 0, 1 and 3; HIV‐1 MVA vaccine at months 9 and 21
Number of subjects: 79
Study 24321091 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational sessions
Number of subjects: 79
Study 24321091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-screening workshops
Number of subjects: 79
Study 24321091 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial screenings
Number of subjects: 79
Study 20638452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vaccine
Number of subjects: 2389
Study 20638452 — intervention group
Group type: COMPARATOR
Intervention: Injectable vaccine
Number of subjects: 2389
Study 20638452 — intervention group
Group type: EXPERIMENTAL
Intervention: Study interventions (enhanced advertising, choice of vaccine type, and incentive)
Number of subjects: 2389
Study 20638452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional vaccine choice
Number of subjects: 2389
Study 18995180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 0
Study 18995180 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 0
Study 16386854 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 68
Study 12504040 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiochemotherapy (Arm B: 70 Gy in 35 fractions with three cycles of a 4-day regimen containing carboplatin and 5-fluorouracil)
Number of subjects: 226
Study 12504040 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiochemotherapy (Arm B)
Number of subjects: 226
Study 12504040 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (Arm A: 70 Gy in 35 fractions)
Number of subjects: 226
Study 12504040 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (Arm A)
Number of subjects: 226
Study 10617952 — intervention group
Group type: EXPERIMENTAL
Intervention: High iron bioavailability diet (14.4 mg nonheme Fe/d, 1.8 mg heme Fe/d)
Number of subjects: 31
Study 10617952 — intervention group
Group type: EXPERIMENTAL
Intervention: Low iron bioavailability diet (15.3 mg nonheme Fe/d, 0.1 mg heme Fe/d)
Number of subjects: 31
Study 10617952 — intervention group
Group type: COMPARATOR
Intervention: Comparison of high and low bioavailability diets
Number of subjects: 31
Study 10617952 — intervention group
Group type: COMPARATOR
Intervention: Low bioavailability diet
Number of subjects: 31
Study 10617952 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte incorporation of absorbed iron
Number of subjects: 31
Study 9097256 — intervention group
Group type: EXPERIMENTAL
Intervention: NMS-assisted arm ergometry (Group I, n = 12)
Number of subjects: 34
Study 9097256 — intervention group
Group type: EXPERIMENTAL
Intervention: NMS-assisted arm ergometry followed by arm ergometry alone (Group II, n = 11)
Number of subjects: 34
Study 9097256 — intervention group
Group type: COMPARATOR
Intervention: Arm ergometry alone (Group III, n = 11)
Number of subjects: 34
Study 9097256 — intervention group
Group type: COMPARATOR
Intervention: NMS-assisted arm ergometry (Group I) vs Arm ergometry alone (Group III)
Number of subjects: 34
Study 9097256 — intervention group
Group type: COMPARATOR
Intervention: NMS-assisted arm ergometry followed by arm ergometry alone (Group II) vs Arm ergometry alone (Group III)
Number of subjects: 34
Study 1397769 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital noise suppression algorithm (INTEL)
Number of subjects: 20
Study 1397769 — intervention group
Group type: COMPARATOR
Intervention: Nucleus cochlear implant users
Number of subjects: 20
Study 1397769 — intervention group
Group type: COMPARATOR
Intervention: Normally hearing adults
Number of subjects: 20
Study 3859954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg PGE2 gel placed retroamnially by means of a balloon catheter
Number of subjects: 0
Study 3859954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg PGE2 gel applied endocervically
Number of subjects: 0
Study 3859954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 gel applied endocervically
Number of subjects: 0
Study 3859954 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg PGE2 given pericervically through a portio adapter
Number of subjects: 0
Study 3859954 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg PGE2 placed intravaginally in form of a single vaginal tablet
Number of subjects: 0
Study 3859954 — intervention group
Group type: COMPARATOR
Intervention: Control group (only vaginal examination)
Number of subjects: 0
Study 30113178 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite health promotion intervention
Number of subjects: 202
Study 30113178 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 202
Study 30511680 — intervention group
Group type: EXPERIMENTAL
Intervention: APD machine made in China
Number of subjects: 260
Study 30511680 — intervention group
Group type: COMPARATOR
Intervention: Imported APD machine
Number of subjects: 260
Study 27583475 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 27
Study 27583475 — intervention group
Group type: COMPARATOR
Intervention: Conventional lifestyle advice (control)
Number of subjects: 27
Study 24779483 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the association between viral load and contagiousness (low viral load condition)
Number of subjects: 752
Study 24779483 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the association between viral load and contagiousness (high viral load condition)
Number of subjects: 752
Study 24779483 — intervention group
Group type: COMPARATOR
Intervention: No information about the association between viral load and contagiousness (control group)
Number of subjects: 752
Study 23519393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough Quality-of-Life Questionnaire (CQLQ)
Number of subjects: 0
Study 23519393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23519393 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0
Study 20452468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild exercise
Number of subjects: 34
Study 18787893 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 250 mg BD
Number of subjects: 81
Study 18787893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 15696558 — intervention group
Group type: EXPERIMENTAL
Intervention: High exercise adherence
Number of subjects: 134
Study 12848634 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib (40 mg b.d.)
Number of subjects: 186
Study 12848634 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg b.d.)
Number of subjects: 186
Study 12848634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 10342404 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 16
Study 10342404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8663954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous-only excisions
Number of subjects: 40
Study 8663954 — intervention group
Group type: COMPARATOR
Intervention: Cutaneous-vestibular excisions
Number of subjects: 40
Study 1992102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 200 mg daily
Number of subjects: 7
Study 6744646 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (alpha‐1 adrenoceptor agonist)
Number of subjects: 0
Study 6744646 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (beta 2‐adrenoceptor agonist)
Number of subjects: 0
Study 6744646 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not specified)
Number of subjects: 0
Study 30891886 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 720
Study 30891886 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 720
Study 30212253 — intervention group
Group type: COMPARATOR
Intervention: Standard protein diet (1.1 g·kg‐1·day‐1, 39% fat)
Number of subjects: 17
Study 30212253 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein diet (2.1 g·kg‐1·day‐1, 23% fat)
Number of subjects: 17
Study 27069104 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Balloon (PEB)
Number of subjects: 136
Study 27069104 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 136
Study 24906174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 20 mg + Enalapril 20 mg
Number of subjects: 1039
Study 24906174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1039
Study 24906174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine (10 or 20 mg) or Enalapril (10 or 20 mg)
Number of subjects: 1039
Study 21293245 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) and observation
Number of subjects: 0
Study 21293245 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) and whole brain radiation therapy
Number of subjects: 0
Study 20559273 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine (0.1g) and Limontar (0.25g) 3 times a day
Number of subjects: 112
Study 20559273 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (treatment of glycemia, vasoactive drugs)
Number of subjects: 112
Study 22281182 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat 200 mg t.i.d. for 8 days
Number of subjects: 11
Study 22281182 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 days
Number of subjects: 11
Study 16339692 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum non-transferrin-bound iron (NTBI) levels measured weekly during transfusion cycles
Number of subjects: 15
Study 16339692 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term monitoring of NTBI levels
Number of subjects: 15
Study 12559229 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR-evoking stimulation (sound, voice, and rapid inspiration)
Number of subjects: 22
Study 12559229 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR potential distribution measured in 10 subjects
Number of subjects: 22
Study 12559229 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR potential on the dorsum of the hand
Number of subjects: 22
Study 12559229 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated equivalent current dipole (ECD)
Number of subjects: 22
Study 10536647 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-Hip Ratio (WHR)
Number of subjects: 263
Study 10536647 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 263
Study 10536647 — intervention group
Group type: COMPARATOR
Intervention: Control for genetic influences
Number of subjects: 263
Study 8683231 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11) at a dose of 145 mg/m2 administered as a 90-minute infusion with G-CSF and antidiarrheal support
Number of subjects: 40
Study 1806467 — intervention group
Group type: COMPARATOR
Intervention: Parlodel R (conventional bromocriptine) 2.5 mg b.i.d. for 2 weeks, then doubled for 2 weeks
Number of subjects: 12
Study 1806467 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel SRO (slow-release bromocriptine) 5 mg once daily for 2 weeks, then doubled for 2 weeks
Number of subjects: 12
Study 1806467 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel SRO (slow-release bromocriptine) 2.5-10 mg daily for 6 months
Number of subjects: 12
Study 6410266 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured psychotherapeutic counselling during detoxification
Number of subjects: 25
Study 6410266 — intervention group
Group type: COMPARATOR
Intervention: Standard detoxification without counselling
Number of subjects: 25
Study 29224960 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise
Number of subjects: 57
Study 29224960 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 57
Study 28077379 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (RS)
Number of subjects: 75
Study 28077379 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose
Number of subjects: 75
Study 28077379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 28077379 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (RS) and Polydextrose
Number of subjects: 75
Study 25975969 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg/kg bolus over 5 minutes, followed by 1.5 mg/kg/h continuous infusion until end of surgery)
Number of subjects: 0
Study 25975969 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0
Study 25975969 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 0
Study 24093844 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 7.5 mg twice a day
Number of subjects: 19102
Study 24093844 — intervention group
Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 19102
Study 20364698 — intervention group
Group type: EXPERIMENTAL
Intervention: RFC (rituximab, fludarabine, and cyclophosphan)
Number of subjects: 229
Study 20364698 — intervention group
Group type: EXPERIMENTAL
Intervention: FCM (fludarabine, cyclophosphan, and mitoxantrone)
Number of subjects: 229
Study 20364698 — intervention group
Group type: EXPERIMENTAL
Intervention: FC (fludarabine and cyclophosphan)
Number of subjects: 229
Study 19146054 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate autogenous bone and platelet-rich plasma (PRP)
Number of subjects: 4
Study 19146054 — intervention group
Group type: COMPARATOR
Intervention: Particulate autogenous bone alone
Number of subjects: 4
Study 16388984 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV gB vaccine
Number of subjects: 292
Study 16388984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 12804020 — intervention group
Group type: EXPERIMENTAL
Intervention: Algal extract in safflower oil (2 mg of astaxanthin each, 3 gelcaps per day)
Number of subjects: 35
Study 12804020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (safflower oil only, 3 gelcaps per day)
Number of subjects: 35
Study 10826575 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg SR49059
Number of subjects: 100
Study 10826575 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg SR49059
Number of subjects: 100
Study 10826575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8829862 — intervention group
Group type: EXPERIMENTAL
Intervention: Stylet retained for entire intubation procedure
Number of subjects: 60
Study 8829862 — intervention group
Group type: COMPARATOR
Intervention: Stylet removed after bronchial cuff passed vocal cords
Number of subjects: 60
Study 1642202 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day morning administration of 40 mg famotidine
Number of subjects: 179
Study 1642202 — intervention group
Group type: COMPARATOR
Intervention: Once-a-day bedtime administration of 40 mg famotidine
Number of subjects: 179
Study 1642202 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 179
Study 1642202 — intervention group
Group type: COMPARATOR
Intervention: Bedtime group
Number of subjects: 179
Study 6192636 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating-pressure air-mattresses
Number of subjects: 600
Study 6192636 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-mattresses
Number of subjects: 600
Study 6192636 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600
Study 29706701 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion‐distraction and drop techniques
Number of subjects: 30
Study 29706701 — intervention group
Group type: COMPARATOR
Intervention: Spinal decompression therapy
Number of subjects: 30
Study 26991814 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-Active
Number of subjects: 414
Study 26991814 — intervention group
Group type: COMPARATOR
Intervention: PC-Control
Number of subjects: 414
Study 26991814 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-Combined
Number of subjects: 414
Study 26991814 — intervention group
Group type: COMPARATOR
Intervention: SD
Number of subjects: 414
Study 24506194 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% lidocaine (LDC)
Number of subjects: 24
Study 24506194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) saline
Number of subjects: 24
Study 22666096 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA + FNB (FNB group)
Number of subjects: 39
Study 22666096 — intervention group
Group type: COMPARATOR
Intervention: PMMA only (PMMA group)
Number of subjects: 39
Study 19656349 — intervention group
Group type: EXPERIMENTAL
Intervention: New uniform restrictive transfusion policy
Number of subjects: 603
Study 19656349 — intervention group
Group type: COMPARATOR
Intervention: Standard care policy
Number of subjects: 603
Study 19656349 — intervention group
Group type: EXPERIMENTAL
Intervention: New transfusion policy in two hospitals
Number of subjects: 603
Study 19656349 — intervention group
Group type: EXPERIMENTAL
Intervention: New transfusion policy in third hospital
Number of subjects: 603
Study 19656349 — intervention group
Group type: EXPERIMENTAL
Intervention: Both policies
Number of subjects: 603
Study 18378001 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic features in patients with bipolar mania
Number of subjects: 515
Study 18378001 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS items (grandiosity, delusions, lack of judgment/insight, excitement, suspiciousness/persecution, hostility)
Number of subjects: 515
Study 18378001 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandiosity symptoms of delusional proportions
Number of subjects: 515
Study 15785149 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 15785149 — intervention group
Group type: COMPARATOR
Intervention: Adjusted-dose warfarin (INR 2.0-3.0)
Number of subjects: 0
Study 15785149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (fixed dose)
Number of subjects: 0
Study 11851727 — intervention group
Group type: EXPERIMENTAL
Intervention: d-penicillamine
Number of subjects: 34
Study 11851727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9950380 — intervention group
Group type: COMPARATOR
Intervention: Standard open technique
Number of subjects: 30
Study 9950380 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Four-Step Technique (RFST)
Number of subjects: 30
Study 7778533 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times daily
Number of subjects: 30
Study 7778533 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril 15 mg twice daily
Number of subjects: 30
Study 2318113 — intervention group
Group type: EXPERIMENTAL
Intervention: Threefold basal immunosuppression (low-dose ciclosporin, azathioprine, and prednisolone)
Number of subjects: 100
Study 2318113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourfold basal immunosuppression (with additional poly- or monoclonal antibodies)
Number of subjects: 100
Study 2318113 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional antirejection treatment with poly- or monoclonal antibodies
Number of subjects: 100
Study 7350888 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic intravenous (IV) rate controller
Number of subjects: 0
Study 7350888 — intervention group
Group type: COMPARATOR
Intervention: Standard roller clamp
Number of subjects: 0
Study 31915038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet and resistance training combination
Number of subjects: 90
Study 31915038 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-fat diet
Number of subjects: 90
Study 31915038 — intervention group
Group type: COMPARATOR
Intervention: High-protein diet
Number of subjects: 90
Study 31030282 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults during speech production in response to temporally unpredictable stimuli
Number of subjects: 2
Study 31030282 — intervention group
Group type: COMPARATOR
Intervention: Younger adults during speech production in response to temporally unpredictable stimuli
Number of subjects: 2
Study 31030282 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults during button press motor reaction time tasks
Number of subjects: 2
Study 31030282 — intervention group
Group type: COMPARATOR
Intervention: Younger adults during button press motor reaction time tasks
Number of subjects: 2
Study 27458993 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 100
Study 27458993 — intervention group
Group type: COMPARATOR
Intervention: Artesunate combination therapy (ACT)
Number of subjects: 100
Study 27458993 — intervention group
Group type: COMPARATOR
Intervention: ACT
Number of subjects: 100
Study 27458993 — intervention group
Group type: COMPARATOR
Intervention: Quinine vs ACT
Number of subjects: 100
Study 25597369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 120
Study 25597369 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lorazepam
Number of subjects: 120
Study 23521105 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway Supreme (Supreme) at 60 cm H(2)O
Number of subjects: 180